ClinicalTrials.gg
CompletedNCT01135992BEGIN™Updated Jan 22, 2016Results posted

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-22.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
143
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
53rd of 70
143 · median 384
Started
2010
with 11 others
Phase 3
49 of 70
2 open now
Registered
16th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 143 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
  • maximum 10 % by central laboratory analysis
  • Current treatment with basal-oral therapy (BOT) (no prandial insulin ever) consisting of: at least three months with insulin glargine once daily (average prescribed dose must have been unchanged (within plus/minus 10%) for four weeks prior to Visit 1 as confirmed by patient records or verbal confirmation by the subject) in combination with stable (unchanged doses for at least 3 months prior to Visit 1) OAD (metformin, insulin secretagogues, pioglitazone, sitagliptin or alpha-glucosidase-inhibitor) treatment in any approved (according to label) dose or combination

Exclusion criteria

Exclusion Criteria:

  • Use within the last three months prior to Visit 1 of: Exenatide, Liraglutide or Thiazoledinediones (TZDs) other than Pioglitazone
  • Cardiovascular disease (CVD) defined as: stroke; decompensated heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty within the last six months prior to Visit 1
  • Recurrent severe hypoglycaemia (more than one severe hypoglycaemic episode during the last 12 months), or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous six months
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate measures according to local requirements
  • Previous participation in this trial. Participation is defined as started on trial medication. Rescreening of screening failures is allowed only once within the limits of the recruitment period
  • Known or suspected to trial products or related products
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    IGlar/IDeg

    Drug: insulin glargine

  • Experimental
    IDeg 3TW

    Drug: insulin degludec

Interventions

  • Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks

  • Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec

07

What researchers measure

Primary outcomes

  1. HbA1c (Glycosylated Haemoglobin)

    HbA1C at week 4 and 16

    Time frame: Week 4 and Week 16

Secondary outcomes

  1. Fasting Plasma Glucose (FPG)

    FPG at week 4 and 16

    Time frame: Week 4 and Week 16

  2. Change in Body Weight

    Change from baseline in body weight after week 4 and after week 16

    Time frame: Week 0, Week 4, Week 16

  3. Rate of Treatment Emergent Adverse Events (AEs)

    Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

    Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)

  4. Rate of Confirmed Hypoglycaemic Episodes

    Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.

    Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)

  5. Rate of Nocturnal Confirmed Hypoglycaemic Episodes

    Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.

    Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)

08

Results

Posted Jan 22, 2016

Participant flow

The trial was conducted at 27 sites in the United States of America (U.S.)

Participant flow — Overall Study
MilestoneIGlar/IDeg
Started143
Exposed142
Full analysis set129
Completed122
Not completed21
Withdrew: Adverse event1
Withdrew: Lack of efficacy1
Withdrew: Protocol violation2
Withdrew: Withdrawal criteria10
Withdrew: Unclassified7

Outcome measures

PrimaryHbA1c (Glycosylated Haemoglobin)

HbA1C at week 4 and 16

Time frame:
Week 4 and Week 16
Reported as:
Mean · percentage of glycosylated haemoglobin
HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinIGlar/IDeg
Week 4 (N=128) (IGlar)7.4 ± 1.0
Week 16 (N=122)(IDeg)7.2 ± 1.1
SecondaryFasting Plasma Glucose (FPG)

FPG at week 4 and 16

Time frame:
Week 4 and Week 16
Reported as:
Mean · mmol/L
Fasting Plasma Glucose (FPG)
mmol/LIGlar/IDeg
Week 4 (N=128) (IGlar)7.0 ± 2.3
Week 16 (N=122) (IDeg)6.3 ± 2.2
SecondaryChange in Body Weight

Change from baseline in body weight after week 4 and after week 16

Time frame:
Week 0, Week 4, Week 16
Reported as:
Mean · kg
Change in Body Weight
kgIGlar/IDeg
Week 4(N= 142) (IGlar)0.1 ± 0.4
Week 16 (N=129) (IDeg)0.6 ± 2.2
SecondaryRate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

Time frame:
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Reported as:
Number · events per 100 patient years
Rate of Treatment Emergent Adverse Events (AEs)
events per 100 patient yearsIGlar/IDeg
Adverse events (N=142)(week 4)(IGlar)370
Serious AEs (N=142 ) (week 4)(IGlar)9
Severe AEs (N=142)(week 4) (IGlar)19
Moderate AEs (N=142) (week 4)(IGlar)102
Mild AEs (N=142)(week 4) (IGlar)250
Fatal AEs (N=142) (week 4) (IGlar)0
Adverse events (N=129) (week 16) (IDeg)424
Serious AEs (n=129) (week 16) (IDeg)7
Severe AEs (N=129) (week 16) (IDeg)10
Moderate AEs (N=129) (week 16) (IDeg)132
Mild AEs (N=129) (week 16) (IDeg)280
Fatal AEs (N=129) (week 16) (IDeg)0
Adverse Events (N=142) (Total)409
Serious AEs (N=142) (Total)8
Severe AEs (N=142) (Total)13
Moderate AEs (N=142) (Total)124
Mild AEs (N=142) (Total)273
Fatal AEs (N=142)(Total)0
SecondaryRate of Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.

Time frame:
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Reported as:
Number · episodes per 100 patient years
Rate of Confirmed Hypoglycaemic Episodes
episodes per 100 patient yearsIGlar/IDeg
IGlar (N=142) (week 4)453
IDeg (N=129) (week 16)424
SecondaryRate of Nocturnal Confirmed Hypoglycaemic Episodes

Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.

Time frame:
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Reported as:
Number · episodes per 100 patient years
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
episodes per 100 patient yearsIGlar/IDeg
IGlar (week 4) (N=142)111
IDeg (week 16) (N=129)83

Adverse events

Collected over The adverse events were collected in a time frame of 0-4 weeks (IGlar) and 4-16 weeks (IDeg 3TW). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGlar/IDeg—3/142 (2.1%)0/142 (0%)
Most frequent serious events
Most frequent serious events
EventIGlar/IDeg
Cholelithiaisis (IDeg)Hepatobiliary disorders1/129
Carotid artery occlusion (IDeg)Nervous system disorders1/129
Cholelithiasis (Total)Hepatobiliary disorders1/142
Lumbar spinal stenosis (IGlar)Musculoskeletal and connective tissue disorders1/142
Lumbar spinal stenosis (Total)Musculoskeletal and connective tissue disorders1/142
Carotid artery occlusion (Total)Nervous system disorders1/142
Cholelithiasis (IGlar)Hepatobiliary disorders0/142
Lumbar spinal stenosis (IDeg)Musculoskeletal and connective tissue disorders0/129
Carotid artery occlusion (IGlar)Nervous system disorders0/142

Baseline characteristics

Full Analysis set (FAS)-Includes 129 subjects only as 13 subjects did not receive IDeg.

Age, Continuous
Age, Continuous(years)IGlar/IDeg
Mean58.7 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)IGlar/IDeg
Female43
Male86
HbA1c (glycosylated haemoglobin) at baseline
HbA1c (glycosylated haemoglobin) at baseline(percentage of glycosylated haemoglobin)IGlar/IDeg
Mean7.5 ± 1.1
Fasting plasma glucose (FPG) at baseline
Fasting plasma glucose (FPG) at baseline(mmol/L)IGlar/IDeg
Mean7.0 ± 2.2
Body weight at baseline
Body weight at baseline(kg)IGlar/IDeg
Mean99.3 ± 20.4
09

Study locations

27 sites
  • Novo Nordisk Clinical Trial Call Center
    Goodyear, Arizona 85395, United States
  • Novo Nordisk Clinical Trial Call Center
    Phoenix, Arizona 85018, United States
  • Novo Nordisk Clinical Trial Call Center
    Anaheim, California 92801, United States
  • Novo Nordisk Clinical Trial Call Center
    Chino, California 91710, United States
  • Novo Nordisk Clinical Trial Call Center
    Concord, California 94520, United States
  • Novo Nordisk Clinical Trial Call Center
    Fresno, California 93720, United States
  • Novo Nordisk Clinical Trial Call Center
    Greenbrae, California 94904, United States
  • Novo Nordisk Clinical Trial Call Center
    Palm Springs, California 92262-6972, United States
  • Novo Nordisk Clinical Trial Call Center
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Clinical Trial Call Center
    Chicago, Illinois 60616, United States
  • Novo Nordisk Clinical Trial Call Center
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Clinical Trial Call Center
    Metairie, Louisiana 70006-2930, United States
  • Novo Nordisk Clinical Trial Call Center
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Clinical Trial Call Center
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Clinical Trial Call Center
    Dover, New Hampshire 03820, United States
  • Novo Nordisk Clinical Trial Call Center
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Clinical Trial Call Center
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Clinical Trial Call Center
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Clinical Trial Call Center
    Albany, New York 12206, United States
  • Novo Nordisk Clinical Trial Call Center
    Charlotte, North Carolina 28209, United States
  • Novo Nordisk Clinical Trial Call Center
    Melrose Park, Pennsylvania 19027, United States
  • Novo Nordisk Clinical Trial Call Center
    Pittsburgh, Pennsylvania 15224-2215, United States
  • Novo Nordisk Clinical Trial Call Center
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Clinical Trial Call Center
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Clinical Trial Call Center
    Austin, Texas 78731, United States
  • Novo Nordisk Clinical Trial Call Center
    Fort Worth, Texas 76113, United States
  • Novo Nordisk Clinical Trial Call Center
    Olympia, Washington 98502, United States
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 5 years 2 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2010
First posted
Jun 3, 2010
Start
Jun 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
Feb 24, 2011
Results first posted
Jan 22, 2016
Last update
Jan 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01135992
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 3, 2010
Start date
Jun 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Jan 22, 2016
Last update
Jan 22, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine

Start the discussion